Evidence map›Paper›PMID 36937677›Full record

ArticleFrontiers in neuroscience2023

Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer's disease continuum.

Hillary Protas, Valentina Ghisays, Dhruman D Goradia, Robert Bauer, Vivek Devadas, Kewei Chen, Eric M Reiman, Yi Su

Open access · goldFull text read
In one paragraph

Article in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Hillary ProtasBanner Alzheimer's Institute, Phoenix, AZ, United States.
Valentina GhisaysBanner Alzheimer's Institute, Phoenix, AZ, United States.
Dhruman D GoradiaBanner Alzheimer's Institute, Phoenix, AZ, United States.
Robert BauerBanner Alzheimer's Institute, Phoenix, AZ, United States.
Vivek DevadasBanner Alzheimer's Institute, Phoenix, AZ, United States.
Kewei ChenBanner Alzheimer's Institute, Phoenix, AZ, United States.
Eric M ReimanBanner Alzheimer's Institute, Phoenix, AZ, United States.
Yi SuBanner Alzheimer's Institute, Phoenix, AZ, United States.
Banner Alzheimer’s InstituteAlzheimer's Association · USArizona Alzheimer’s ConsortiumArizona State University · USUniversity of Arizona · US

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
APOE in the Predisposition to, Protection from and Prevention of Alzheimer's DiseaseR01AG069453 · NIA · BANNER HEALTH · PI ASHTON, NICHOLAS, LANGBAUM, JESSICA BROOKE · 2020 to 2025
$27.4M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI HEATHER Allyson BIMONTE-NELSON · 2021 to 2026
$24.9M
PET, APOE & the Preclinical Course of Alzheimer's DiseaseR01AG031581 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI CASELLI, RICHARD J., REIMAN, ERIC MICHAEL · 2008 to 2018
$16.6M
Tracer harmonization for amyloid and tau PET imaging using statistical and deep learning techniquesRF1AG073424 · NIA · BANNER HEALTH · PI SU, YI · 2022 to 2022
$2.3M
NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG031581NIA NIH HHS R01 AG069453NIA NIH HHS RF1 AG073424NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904
6 · The paper itself

Abstract

Introduction: Tau PET imaging has emerged as an important tool to detect and monitor tangle burden in vivo in the study of Alzheimer's disease (AD). Previous studies demonstrated the association of tau burden with cognitive decline in probable AD cohorts. This study introduces a novel approach to analyze tau PET data by constructing individualized tau network structure and deriving its graph theory-based measures. We hypothesize that the network- based measures are a measure of the total tau load and the stage through disease. Methods: Using tau PET data from the AD Neuroimaging Initiative from 369 participants, we determine the network measures, global efficiency, global strength, and limbic strength, and compare with two regional measures entorhinal and tau composite SUVR, in the ability to differentiate, cognitively unimpaired (CU), MCI and AD. We also investigate the correlation of these network and regional measures and a measure of memory performance, auditory verbal learning test for long-term recall memory (AVLT-LTM). Finally, we determine the stages based on global efficiency and limbic strength using conditional inference trees and compare with Braak staging. Results: We demonstrate that the derived network measures are able to differentiate three clinical stages of AD, CU, MCI, and AD. We also demonstrate that these network measures are strongly correlated with memory performance overall. Unlike regional tau measurements, the tau network measures were significantly associated with AVLT-LTM even in cognitively unimpaired individuals. Stages determined from global efficiency and limbic strength, visually resembled Braak staging. Discussion: The strong correlations with memory particularly in CU suggest the proposed technique may be used to characterize subtle early tau accumulation. Further investigation is ongoing to examine this technique in a longitudinal setting.

Indexed as

ADNIAlzheimer’s diseaseflortaucipir PETgraph theorytangle burden

Identifiers

PMID36937677
PMCPMC10017746
OpenAlexW4322773076

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read18
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.